Literature DB >> 19151631

Advances in cancer therapeutics.

A Sparreboom, J Verweij.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19151631      PMCID： PMC2629589          DOI： 10.1038/clpt.2008.259

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  23 in total

Review 1.  Applying the discovery of the Philadelphia chromosome.

Authors:  Daniel W Sherbenou; Brian J Druker
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

2.  Terminal ballistics of kinase inhibitors: there are no magic bullets.

Authors:  Michael L Maitland; Mark J Ratain
Journal:  Ann Intern Med       Date:  2006-11-07       Impact factor: 25.391

3.  Challenges in prescribing drugs for children with cancer.

Authors:  Paolo Paolucci; Kathy Pritchard Jones; Maria del Carmen Cano Garcinuno; Mariana Catapano; Achille Iolascon; Adriana Ceci
Journal:  Lancet Oncol       Date:  2008-02       Impact factor: 41.316

4.  Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

Authors:  Ron H J Mathijssen; Floris A de Jong; Walter J Loos; Jessica M van der Bol; Jaap Verweij; Alex Sparreboom
Journal:  Oncologist       Date:  2007-08

Review 5.  Drug discovery and development in the age of molecular medicine.

Authors:  P Vallance; M Levick
Journal:  Clin Pharmacol Ther       Date:  2007-10       Impact factor: 6.875

6.  Imaging as a biomarker for therapy response: cancer as a prototype for the creation of research resources.

Authors:  G McLennan; L Clarke; R J Hohl
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

7.  Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?

Authors:  R A Boyd; R L Lalonde
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

8.  Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.

Authors:  Jayne M Stommel; Alec C Kimmelman; Haoqiang Ying; Roustem Nabioullin; Aditya H Ponugoti; Ruprecht Wiedemeyer; Alexander H Stegh; James E Bradner; Keith L Ligon; Cameron Brennan; Lynda Chin; Ronald A DePinho
Journal:  Science       Date:  2007-09-13       Impact factor: 47.728

9.  Noninvasive assessment of cancer response to therapy.

Authors:  Zhaozhong Han; Allie Fu; Hailun Wang; Roberto Diaz; Ling Geng; Halina Onishko; Dennis E Hallahan
Journal:  Nat Med       Date:  2008-02-24       Impact factor: 53.440

10.  Progress against cancer?

Authors:  J C Bailar; E M Smith
Journal:  N Engl J Med       Date:  1986-05-08       Impact factor: 91.245
View more
  10 in total

1.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

Review 2.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Authors:  Michelle A Rudek; Charles Flexner; Richard F Ambinder
Journal:  Lancet Oncol       Date:  2011-05-12       Impact factor: 41.316

3.  Utilizing In Vitro Dissolution-Permeation Chamber for the Quantitative Prediction of pH-Dependent Drug-Drug Interactions with Acid-Reducing Agents: a Comparison with Physiologically Based Pharmacokinetic Modeling.

Authors:  Andy Z X Zhu; Ming-Chih David Ho; Christopher K Gemski; Bei-Ching Chuang; Mingxiang Liao; Cindy Q Xia
Journal:  AAPS J       Date:  2016-09-06       Impact factor: 4.009

Review 4.  Noncoding RNAs: potential regulators in cardioncology.

Authors:  Shambhabi Chatterjee; Shashi Kumar Gupta; Christian Bär; Thomas Thum
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-11-09       Impact factor: 4.733

5.  An Observational Study to Assess the Socioeconomic Status and Demographic Profile of Advanced Cancer Patients Receiving Palliative Care in a Tertiary-Level Cancer Hospital of Eastern India.

Authors:  Gaurav Kumar; Nibedita Panda; Rakesh Roy; Gautam Bhattacharjee
Journal:  Indian J Palliat Care       Date:  2018 Oct-Dec

Review 6.  Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.

Authors:  Neeraj Gupta; Michael J Hanley; Paul M Diderichsen; Huyuan Yang; Alice Ke; Zhaoyang Teng; Richard Labotka; Deborah Berg; Chirag Patel; Guohui Liu; Helgi van de Velde; Karthik Venkatakrishnan
Journal:  Clin Pharmacol Ther       Date:  2018-03-23       Impact factor: 6.875

7.  Intrinsic and Extrinsic Pharmacokinetic Variability of Small Molecule Targeted Cancer Therapy.

Authors:  Eric Reyner; Bert Lum; Jing Jing; Matts Kagedal; Joseph A Ware; Leslie J Dickmann
Journal:  Clin Transl Sci       Date:  2019-12-12       Impact factor: 4.689

8.  'The same old story': thoughts on authorized doses of anticancer drugs.

Authors:  Fausto Meriggi; Alberto Zaniboni
Journal:  Ther Adv Med Oncol       Date:  2020-02-22       Impact factor: 8.168

Review 9.  Long non-coding RNAs and microRNAs as crucial regulators in cardio-oncology.

Authors:  Sarath Babu Nukala; Jordan Jousma; Yoonje Cho; Won Hee Lee; Sang-Ging Ong
Journal:  Cell Biosci       Date:  2022-03-04       Impact factor: 7.133

10.  GSTP1 rs1695 is associated with both hematological toxicity and prognosis of ovarian cancer treated with paclitaxel plus carboplatin combination chemotherapy: a comprehensive analysis using targeted resequencing of 100 pharmacogenes.

Authors:  Tomoko Yoshihama; Koya Fukunaga; Akira Hirasawa; Hiroyuki Nomura; Tomoko Akahane; Fumio Kataoka; Wataru Yamagami; Daisuke Aoki; Taisei Mushiroda
Journal:  Oncotarget       Date:  2018-07-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.